tbuckley/cabot-search huggingface dataset:
785O PIVOT IO 001: First disclosure of efficacy and safety of bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) vs NIVO monotherapy in advanced melanoma (MEL)
Authors: A. Diab, H.J. Gogas, S.K. Sandhu, G.V. Long, P.A. Ascierto, J. Larkin, M. Sznol, F.A. Franke, T-E. Ciuleanu, E. Muñoz Couselo, A. Perfetti, C. Lebbe, F. Meier, B. Curti, C. Rojas, H. Yang, M. Zhou, S. Ravimohan, M.A. Tagliaferri, N. Khushanlani
Journal: Annals of Oncology (2022)
964P PACIFIC on the West Coast: Exploring reasons for not receiving consolidative durvalumab in the treatment of locally advanced lung cancer
Authors: J. Feng, M-H. Denault, S. Kuang, A. Shokoohi, B. Leung, M. Liu, E. Berthelet, J. Laskin, S. Sun, T. Zhang, C. Ho, B. Melosky
Journal: Annals of Oncology (2022)
1071P Trustworthy artificial intelligence models using real-world and circulating genomics data for the prediction of immunotherapy efficacy in non-small cell lung cancer patients
Authors: A. Prelaj, A. Bottiglieri, L. Provenzano, A. Spagnoletti, L. Mazzeo, V. Miskovic, M. Ganzinelli, G. Lo Russo, R. Ferrara, C. Proto, A. De Toma, M. Brambilla, M. Occhipinti, S. Manglaviti, T. Beninato, A. Rametta, M.C. Garassino, F.G.M. De Braud, F. Trovò, A. Pedrocchi
Journal: Annals of Oncology (2022)
336P Prognostic and predictive value of Immunoscore in stage III colorectal cancer in the combined SCOT and IDEA-HORG studies
Authors: D. Church, J. Hay, O.J. Sansom, None N. Maka, K.A. Oien, T.J. Iveson, M.P. Saunders, J. Edwards, A. Harkin, I. Boukovinas, E. Moustou, I. Messaritakis, M. Chondrozoumaki, V. Georgoulias, I. Boquet, F. Pages, A. Catteau, J. Galon, C. Kelly, I. Souglakos
Journal: Annals of Oncology (2022)
282MO Brain metastases: Real-life treatment patterns, survival and patient-reported outcomes – Results from a population-based, prospective study in 914 patients
Authors: O.E. Yri, G.L. Astrup, A.T. Karlsson, Ø. Paulsen, R. Van Helvoirt, J-Å. Lund, M-I. Taran, M. Jensen Hjermstad, M. Birketvedt, E. Bjerkeset, N. Aass, S. Kaasa
Journal: Annals of Oncology (2022)
659MO Pembrolizumab with or without chemotherapy for first-line treatment of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 5-year results from KEYNOTE-048
Authors: M. Tahara, R. Greil, D. Rischin, K.J. Harrington, B. Burtness, G. De Castro, A. Psyrri, I. Brana, P. Neupane, Å. Bratland, T. Fuereder, B.G.M. Hughes, R. Mesia Nin, N. Ngamphaiboon, T. Rordorf, W.Z. Wan Ishak, J. Lin, B. Gumuscu, N. Lerman, D. Soulieres
Journal: Annals of Oncology (2022)
657MO Effectiveness of geriatric assessment-driven interventions on quality of life for 2 years in older patients with head and neck cancer: Results from the EGeSOR trial
Authors: C. Lafont, E. Paillaud, C. Bertolus, M. Baron, P. Caillet, E. Bouvard, M. Laurent, D. Salvan, L. Chaumette, L. De Decker Lemarcis, B. Piot, B. Barry, A. Raynaud-Simon, E. Sauvaget, A. Minard, A. Anota, H. Panjo, L. Brugel, F. Canouï-Poitrine
Journal: Annals of Oncology (2022)
328P Association of skeletal muscle loss with patient-reported treatment toxicity among colon cancer patients receiving adjuvant chemotherapy
Authors: K. Smit, J.W.G. Derksen, W.B. Veldhuis, P. Moeskops, D.W. Sommeijer, L. van Leeuwen-Snoeks, M. Koopman, A.M. May
Journal: Annals of Oncology (2022)
294P Adult population with BRAF-mutated (BRAFmut) and NF1-mutated (NF1mut) gliomas. Analysis of the potential role of targeted therapy (TT) in these patients (pts)
Authors: M.J. Lostes Bardaji, M.A. Rezqallah Aron, M. Gonzalez Rodriguez, G. Villacampa Javierre, E. Martinez Saez, C. Auger, X. Maldonado, F. Martinez Ricarte, J. Tabernero, J. Carles Galceran, E. Garralda, M. Vieito Villar
Journal: Annals of Oncology (2022)
141MO Pathological response and early survival data according to TNBCtype4 classifier in operable triple-negative breast cancer (TNBC) treated with neoadjuvant carboplatin and docetaxel
Authors: I. Echavarria Diaz-Guardamino, S. Lopez-Tarruella Cobo, M. Del Monte-Millan, E. Alvarez, Y. Jerez, F. Moreno Anton, J.Á. García Saenz, T. Massarrah, I. Ocaña, M. Cebollero, A.I. Ballesteros Garcia, U. Bohn Sarmiento, H. Gomez, H.A. Fuentes, B. Herrero Lopez, S. Gamez Casado, O. Bueno, M.J. Jiménez-Santos, M. Roche-Molina, M. Martin Jimenez
Journal: Annals of Oncology (2022)
617O Lemzoparlimab, a differentiated anti-CD47 monoclonal antibody, in combination with azacitidine (AZA) in patients with newly diagnosed higher risk myelodysplastic syndrome (HR-MDS): Initial clinical results
Authors: Z. Xiao, C. Chang, Q. Li, X. Yan, T. Qin, H. Tong, M. Dai, Y. He, J. Weng, J. Li, S. Gao, R. Fu, X. Wei, X. Ma, Y. Zhang, W. Huang, Q. Wang, L. Gu, Y. Meng, A. Zhu
Journal: Annals of Oncology (2022)
374P Influence of sex on safety and efficacy in BRAF-V600E mutated metastatic colorectal cancer (mCRC) treated with encorafenib-cetuximab +/-binimetinib (E-C+/-B)
Authors: F.J. Ros Montana, V. Navarro, R. Comas, A. Garcia Rodriguez, D. Gomez, N. Saoudi Gonzalez, P. Vicente, J.L. Cuadra, D. Paez, V. Alonso, A. Hernandez Martinez, D.E. López Valbuena, I. Baraibar Argota, F. Salvà Ballabrera, J. Tabernero, M.E. Elez Fernandez
Journal: Annals of Oncology (2022)
728O Results from phase I dose escalation of IMC-F106C, the first PRAME × CD3 ImmTAC bispecific protein in solid tumors
Authors: O. Hamid, T. Sato, D. Davar, M.K. Callahan, F. Thistlethwaite, R. Aljumaily, M.L. Johnson, H-T. Arkenau, E.E. Ileana Dumbrava, B. Izar, H.A. Chen, S. Marshall, Y. Yuan, M. Deo, S. Stanhope, L. Collins, R. Mundy, S.E. Abdullah, J.S. Lopez
Journal: Annals of Oncology (2022)
479P Synergistic anti-tumor effect of Allocetra-OTS in combination with immune checkpoint inhibitors (ICI)/chemotherapy/CAR T, through in-vivo reprogramming of macrophages
Authors: D. Mevorach, E. Yalon, E. Regev, C. Ankri, O. Hershkovitz, Y. Shabat, B. Reicher
Journal: Annals of Oncology (2022)
708TiP BD4QoL: A multicenter randomized trial for monitoring quality of life (QoL) by intelligent tools in head and neck cancer (HNC) survivors after curative treatment
Authors: S. Cavalieri, C. Vener, M. LeBlanc, L. Lopez Perez, G. Fico, C. Resteghini, D. Monzani, G. Marton, M. Moreira-Soares, D.E. Filippidou, A. Almeida, A. Bilbao, H. Mehanna, S. Singer, S. Thomas, L. Lacerenza, A. Manfuso, F. Mercalli, E. Martinelli, L.F. Licitra
Journal: Annals of Oncology (2022)
561P When to treat the pelvis in node-positive vulvar cancer: Results from the AGO-VOP.2 QS vulva study
Authors: M. Hampl, A. Jaeger, C. Eulenburg, K. Prieske, J. Hambrecht, S. Fuerst, R. Klapdor, S. Heublein, P. Gass, A. Rohner, U. Canzler, S. Becker, M. Bommert, D. Bauerschlag, A. Denecke, L. Hanker, J. Sehouli, C. Dannecker, S. Mahner, L. Woelber
Journal: Annals of Oncology (2022)
740P Anti-cytotoxic T-lymphocyte antigen-4 (CTLA 4) probody BMS-986249 ± nivolumab (NIVO) in patients (pts) with advanced cancers: Updated phase I results
Authors: M. Gutierrez, C.F. Friedman, G.V. Long, P.A. Ascierto, I. Melero, D. Richards, B.R. Bastos, V. Moreno Garcia, M. Uemura, P. Conkling, B.R. Corr, A.M. Kim, L. Zhu, A. Hammell, D. Perumal, A. Chouzy, F. Benavente, O. Awosemo, A. Hannah, D.T. Le
Journal: Annals of Oncology (2022)
413P Primary tumor resection (PTR) in metastatic colorectal cancer (mCRC) patients (pts) treated with upfront chemotherapy (CT) + bevacizumab (BEV): A pooled analysis of TRIBE and TRIBE2 studies
Authors: V. Fanotto, A. Boccaccino, M. Casagrande, F. Bergamo, A. Spagnoletti, D. Santini, C. Antoniotti, G. Allegrini, F. Daniel, V. Nasca, D. Rossini, A. Zaniboni, B. Borelli, M. Carullo, V. Conca, A. Passardi, E. Tamburini, G. Masi, C. Cremolini, N. Pella
Journal: Annals of Oncology (2022)
793P NeoPeLe: A phase II trial of neoadjuvant (NAT) pembrolizumab (Pembro) combined with lenvatinib (Lenva) in resectable stage III melanoma
Authors: G.V. Long, A.J. Spillane, T.E. Pennington, K.F. Shannon, J. Stretch, M. Gonzalez, R.P.M. Saw, S.N. Lo, R.A. Scolyer, A.M. Menzies
Journal: Annals of Oncology (2022)
976P Phase II trial of trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC): Registrational data from DESTINY-Lung01
Authors: B.T. Li, E.F. Smit, Y. Goto, K. Nakagawa, K. Goto, J. Mazieres, D. Uprety, L. Bazhenova, A. Saltos, E. Felip, J. Pacheco, M. Pérol, L. Paz-Ares, K. Saxena, R. Shiga, Y. Cheng, Q. Yan, D. Planchard, P.A. Jänne
Journal: Annals of Oncology (2022)
939P Changes in immune gene signatures after neoadjuvant chemoimmunotherapy treatment in NSCLC patients from NADIM trial
Authors: M. Casarrubios, A. Cruz-Bermudez, B. Sierra-Rodero, C. Martinez, E. Nadal, M.A. Insa Molla, J. Mosquera Martinez, C. Gonzalez Ojea, M. Domine Gomez, M. Majem Tarruella, D. Rodriguez Abreu, A. Martinez-Marti, J. De Castro Carpeno, M. Cobo Dols, G. Lopez Vivanco, R. Bernabe Caro, N. Vinolas Segarra, I.C. Barneto Aranda, B. Massuti Sureda, M. Provencio Pulla
Journal: Annals of Oncology (2022)
1068P Predicting response to pembrolizumab in non-small cell lung cancer using spatial analysis of biopsy images by deep learning
Authors: E. Ofek, J. Bar, A. Zer, C. Mayer, C. Sade Zaltz, L. Litzky, C.J. Langer, C. Davis, C. Solomides, I. Micaily, J.M. Johnson, R. Stapp, Z.L. Quinn, Z. Rachmiel, A. Laniado, M. Matalon, E. Markovits, O. Zelichov, M. Feinmesser, I. Barshack
Journal: Annals of Oncology (2022)
399P Role of geriatric assessment and oncological multidimensional prognostic index in elderly patients with metastatic colorectal cancer in a real-world setting
Authors: F. Bergamo, A. Brunello, L. Procaccio, G. Sergi, M. Gatti, E. Bergo, A. Galiano, G. Tierno, B. Chiusole, A. Feltrin, F. Daniel, A.A. Prete, M.C. De Grandis, V.M. Piva, G. Barsotti, C. Rasola, G. Maddalena, K. Cerma, S. Lonardi, V. Zagonel
Journal: Annals of Oncology (2022)
267P AB-ITALY: The impact of drug-drug interaction on abemaciclib treatment in Italian real world experience
Authors: A. Botticelli, S. Scagnoli, S. Pisegna, A. Toss, A. Fabi, C. Criscitiello, G. D'Auria, M.A. Fabbri, A. Orlandi, V. Barberi, R. Caputo, P. Vici, M. Palleschi, D. Santini, G. Tomasello, E. Ricevuto, None M. Simmaco, R. Preissner, E. Cortesi, P. Marchetti
Journal: Annals of Oncology (2022)
192P A phase II single-arm clinical study of neoadjuvant treatment with pegylated liposomal doxorubicin (PLD) plus cyclophosphamide (C) combined with trastuzumab (H) and pertuzumab (P) in HER2-positive (HER2+) breast cancer (BC)
Authors: Y. Yang, L. Jin, N. Rao, C. Gong, S. Li, Y. Li, J. Wu, J. Zhao, L. Ding, Q. Liu
Journal: Annals of Oncology (2022)
627MO Orelabrutinib plus RCHOP for previously untreated non-germinal center b cell-like (GCB) diffuse large b cell lymphoma (DLBCL) patients with extranodal disease
Authors: M. Wang, Q. Ke, Z. Li, D. Zhou, C. Liao, J. Sun, B. Guo, H. Cen
Journal: Annals of Oncology (2022)
251P Real-world clinical outcomes of palbociclib plus endocrine therapy (ET) in hormone receptor–positive advanced breast cancer: Results from the POLARIS trial
Authors: D. Tripathy, G. Rocque, J.L. Blum, M.S. Karuturi, S. McCune, S. Kurian, M.M. Moezi, D. Anderson, E. Gauthier, Z. Zhang, M. Montelongo, Y. Wang
Journal: Annals of Oncology (2022)
1012P Resistance mechanisms to dual EGFR and MET inhibition in patients with EGFR-mutant MET-amplified non-small cell lung cancer
Authors: K. Wang, R. Du, S. Roy, N. Vokes, Y.Y. Elamin, C. Bueno Hume, F. Skoulidis, C. Gay, G. Blumenschein, F. Fossella, A. Tsao, J.J. Lee, W. Rinsurongkawong, V. Rinsurongkawong, D. Gibbons, A. Vaporciyan, J. Zhang, J. Heymach, M. Altan, X. Le
Journal: Annals of Oncology (2022)
1036P Anlotinib plus docetaxel vs. docetaxel as 2nd-line treatment of advanced non-small cell lung cancer (NSCLC): Updated results from ALTER-L016
Authors: Y. Fang, H. Pan, J. Shou, J. Chen, Q. Guo, W. Hong, C. Rao, Y. Wang, L. Lu, X. Yang, D. Zhu, F. Lan
Journal: Annals of Oncology (2022)
462P TYRA-300: FGFR3 selective and gatekeeper agnostic
Authors: J. Starrett, E. Allen, A.M. Balcer, D.C. Bensen, T. Burn, I. Hoffman, R.L. Hudkins, S. Iyer, M. Neal, K. Nelson, C. Occhino, P. Patel, R.V. Swanson, Q. Ye
Journal: Annals of Oncology (2022)
171P Association of breast cancer therapy with cognitive decline in older women with early breast cancer: Findings from the CLIMB study
Authors: J. Baltussen, M.G.M. Derks, A.A. Lemij, N.A. de Glas, M. Fiocco, E. Linthorst-Niers, A. Vulink, L. Van Gerven, O.R. Guicherit, T. Van Dalen, J.W.S. Merkus, T. Lans, C.C. Van der Pol, S.P. Mooijaart, J.E.A. Portielje, G.J. Liefers
Journal: Annals of Oncology (2022)
1041P Efficacy and safety of chemotherapy after progression on immunotherapy: Results of a multicenter retrospective observational trial
Authors: A. Camerini, F. Mazzoni, V. Scotti, C. Tibaldi, A. Sbrana, L. Calabro, E. Caliman, L.P. Ciccone, M.A. Grosso, A. Chella, D. Amoroso, E. Baldini
Journal: Annals of Oncology (2022)
214MO Sacituzumab govitecan (SG) efficacy in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) metastatic breast cancer (MBC) by HER2 immunohistochemistry (IHC) status in the phase III TROPiCS-02 study
Authors: P. Schmid, J. Cortés, F. Marmé, H.S. Rugo, S.M. Tolaney, M. Oliveira, D. Loirat, K. Jhaveri, O.K. Yoon, M. Motwani, H. Wang, R.J. Delaney, A. Bardia
Journal: Annals of Oncology (2022)
798P NeoTrio – Optimal neoadjuvant (NAT) sequencing of anti-PD-1 and BRAF targeted therapy (TT) in BRAF mutant stage III melanoma: Results of histopathological analysis
Authors: J. Braden, A.J. Potter, E.C. Paver, R. Rawson, A.M. Menzies, M.S. Carlino, G. Au-Yeung, R.P.M. Saw, A.J. Spillane, K.F. Shannon, T.E. Pennington, S. Ch'ng, D. Gyorki, J. Howle, D. Daneshvar, J.S. Wilmott, S.N. Lo, I. Pires da Silva, R.A. Scolyer, G.V. Long
Journal: Annals of Oncology (2022)
110P Characteristics and survival outcomes of patients (pts) with RET fusion-positive (RET-fp) solid tumours receiving non-RET inhibitor (RETi) therapy in a real-world setting
Authors: P. Garrido Lopez, S. Siena, M. Taylor, A. Beringer, W. Bordogna, O. Fajardo, C. Nikolaidis
Journal: Annals of Oncology (2022)
498P Generation of CAR T cells expressing a scFV targeting the hTSHR in thyroid cancer
Authors: M. Ali, L. Paschold, M. Bauer, C. Schultheiß, D. Owczarek, L. Müller, K. Lorenz, B. Edemir, C. Wickenhauser, R. Latif, S. Hüttelmaier, C. Dierks, M. Binder
Journal: Annals of Oncology (2022)
791MO Clinical and tumor characteristics of patients (pts) with recurrence after pathologic response upon neoadjuvant ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma
Authors: J.M. Versluis, R. Elens, I.L.M. Reijers, A.M. Menzies, A.A.M. Van der Veldt, E. Kapiteijn, E.A. Rozeman, M.C. Klop, W. Van Houdt, R.P.M. Saw, C.L. Zuur, T.E. Pennington, B. van de Wiel, R.A. Scolyer, A. Broeks, A.C.J. van Akkooi, G.V. Long, C.U. Blank
Journal: Annals of Oncology (2022)
962P Quality of life at diagnosis for unresectable stage III NSCLC: Initial results from the national prospective study OBSTINATE (GFPC 06-2019)
Authors: C. Ricordel, A. Anota, M. Bernardi, L. Falchero, J.B. Auliac, L. Greillier, O. Bylicki, G. De Chabot, A. Demaegdt, A. Vergnenegre, C. Decroisette, I. Martel-Lafay, C. Chouaid, F. Guisier
Journal: Annals of Oncology (2022)
763P Combined gene signature (T-cell inflamed gene expression profile – TcellinfGEP – &amp; IMMETCOLS) identifies a metabolic rewiring program, key for immune evasion
Authors: H. Oliveres, C. Foguet, M. Nebozhyn, L. Pedrosa, I. Cirrincione, P. Morales, J. Lunceford, T. Gorria, J. Maurel, M. Cascante
Journal: Annals of Oncology (2022)
917P OPTIMA: Improve care for patients with prostate, breast, and lung cancer through artificial intelligence
Authors: J. N’Dow, E.J. Smith, K. Polychronopoulos, A. Cannon, M. Roobol, S. Auweter, M. Thomas, A. Kremer, B. De Meulder, D. Dellamonica, D.P. Alhambra, A. Asiimwe, M. Bussmann, X. Ji, P. Torremante, S. Keller, F. Kube, H. Krueger
Journal: Annals of Oncology (2022)
823P A propensity score weighted comparison of tebentafusp or pembrolizumab versus combination ipilimumab and nivolumab in untreated metastatic uveal melanoma
Authors: J.M. Piulats Rodriguez, S. Piperno-Neumann, P. Rutkowski, P. Nathan, J.C. Hassel, E. Espinosa, L. de la Cruz Merino, S. Ochsenreither, A.N. Shoushtari, M. Orloff, A.K.S. Salama, C. Watkins, H. Goodall, J-F. Baurain
Journal: Annals of Oncology (2022)
408P Prediction of survival using the G8 scale frailty scale in a prospective series of elderly patients with colon cancer
Authors: G. Soler Gonzalez, L. Raventos, R.M. Legido-Diaz, C. Martínez, F. Torrent, M. Martinez Villacampa, F. Losa, C. Santos Vivas, J.C. Ruffinelli Rodriguez, A. Teule, M.R. Gallego, A. Manzana, A. Rios, S. Sánchez, A. Piera, C. Boixareu, R. Salazar, J. Saldaña Cañada
Journal: Annals of Oncology (2022)
773P Differences between hyperprogressive disease and progressive disease in patients receiving immunotherapy
Authors: H.C. Yildirim, D.C.C. Guven, O.H. Aktepe, F. Yilmaz, B.Y. Aktas, G. Guner, O. Dizdar, S. Aksoy, M. Erman, S. Yalcin, S. Kilickap
Journal: Annals of Oncology (2022)
CN35 Workplace violence against cancer nurses during the COVID-19 pandemic: A correlational-predictive study
Authors: G. Catania, N. Pagnucci, R. Alvaro, G. Cicolini, A. Dal Molin, L. Lancia, M. Lusignani, D. Mecugni, P.C. Motta, R. Watson, M. Hayter, F. Napolitano, M. Zanini, L. Sasso, A. Bagnasco
Journal: Annals of Oncology (2022)
512MO Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: An analysis of the IGCCCG Update database
Authors: S. Gillessen, J. Lauritsen, N. Sauvé, A. Tryakin, D.M. Jiang, R.A. Huddart, D.Y.C. Heng, A. Terbuch, E. Winquist, M. Chovanec, M. Hentrich, C.D. Fankhauser, J. Shamash, X. Garcia Del Muro, D.J. Vaughn, A. Heidenreich, A. Jandari, L. Collette, J. Beyer, K.G. Daugaard
Journal: Annals of Oncology (2022)
772P Discovery and exploration of a live bacterial consortium as co-therapy to enhance immune checkpoint inhibitor response in melanoma patients
Authors: M.J. Robinson, K. Vervier, S. Harris, A. Popple, D. Klisko, R. Hudson, G. Bakdash, C. Villemin, C. Booth, D. Adams, S.J. Welsh, P.G. Corrie, T. Lawley
Journal: Annals of Oncology (2022)
712P CAPT: A multicenter randomized controlled trial of perioperative versus postoperative camrelizumab plus apatinib for resectable hepatocellular carcinoma
Authors: X. Bai, Y. Chen, X. Zhang, F. Zhang, X. Liang, C. Zhang, X. Wang, B. Lu, S. Yu, T. Liang
Journal: Annals of Oncology (2022)
732MO The combination of ICT01, a γ9δ2 T cell-activating mAb, plus pembrolizumab induces a broad antitumor immune response and disease control in patients with CPI-failure melanoma, NSCLC and bladder cancer: EVICTION trial
Authors: S. Champiat, M. Wermke, C. Vicier, J.S. de Bono, C. Jungels, N. Vey, N. Kotecki, K. Wetzko, L. Ruhnke, E. Garralda, V. Galvao de Aguiar, P. Lorusso, A. de Gassart, E. Valentin, P. Brune, M. Iche, C. Leparquier, D. Olive, A. Marabelle, P.A. Frohna
Journal: Annals of Oncology (2022)
506P The prognostic utility of neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) in carcinoma of unknown primary (CUP): An experience from a tertiary UK cancer centre
Authors: J.A. Scott, N. Peters, C. Harman, C.L. Mitchell, A-M. Conway, N. Cook
Journal: Annals of Oncology (2022)
288MO Brain-only oligometastatic cancer patients present with longer overall survival than patients with extracranial involvement
Authors: A. Steindl, A.Z. Ahmadi, G.M. Moser, B. Gatterbauer, K. Dieckmann, G. Widhalm, M.A. Hoda, M. Preusser, A.S.S. Berghoff
Journal: Annals of Oncology (2022)
995P Effectiveness of combination of osimertinib with another targeted therapy in advanced EGFR mutated non-small cell lung cancer harbouring other oncogenic drivers: The real-world COMPOSIT study
Authors: C. Mehlman, A. Swalduz, I. Monnet, C. Morin, F. Guisier, H. Curcio, P. Du Rusquec, A. Cortot, V. Gounant, B. Abbar, B. Duchemann, E. Giroux-Leprieur, T. Pierret, F.M. Quilot, J. Cadranel, V. Fallet
Journal: Annals of Oncology (2022)
269P Long-term survival of HER2-positive breast cancer patients with brain metastases: Subanalysis of the BMBC registry
Authors: E. Laakmann, K. Riecke, T. Neunhöffer, T-W. Park-Simon, R. Weide, A. Polasik, M. Schmidt, J. Puppe, P.A. Fasching, T. Hesse, T. Decker, C. Denkert, T.N. Fehm, V. Nekljudova, J. Rey, S. Loibl, V. Mueller, I. Witzel
Journal: Annals of Oncology (2022)
957P Proton-therapy and concurrent chemotherapy in stage III NSCLC: Effects on toxicity and immune therapy
Authors: F. Cortiula, L. Hendriks, R. Wijsman, S. Debakker, M. Steens, S.T. Peeters, A. Michelotti, N.M. Sijtsema, S. Urban, A. Niezink, S. Dursun, G. Bootsma, R. Canters, F. Tohidinezhad, G. Fasola, I. Rinaldi, V. Taasti, R. Houben, D. De Ruysscher
Journal: Annals of Oncology (2022)
640P Healthcare resource consumption, autologous stem cell transplantation and direct costs of multiple myeloma: An Italian real-world picture
Authors: I. Esposito, S. Calabria, G. Ronconi, C. Piccinni, L. Dondi, L. Dondi, A. Addesi, A. Pedrini, A.P. Maggioni, N. Martini
Journal: Annals of Oncology (2022)
553P Real-world data on dostarlimab in post-platinum mismatch repair deficient (dMMR)/ microsatellite instability high (MSI-H) advanced/recurrent (A/R) endometrial cancer: Descriptive analysis of the French cohort temporary authorization of use (ATU)
Authors: M.J. Rodrigues, L. Eberst, P. Follana, V. Brunel, L. Gauthier, V.J. Jacquemin, C. Tessier, N. El Mouaddin, P. Boudier, F. Fiteni, E. Angeli, S. Roche, I. Bonnet, C. Deldycke, N. Delanoy, R. Sabatier, R. Flippot, T. De La Motte Rouge
Journal: Annals of Oncology (2022)
1043P Clinical predictors of benefit from pembrolizumab (pembro) or pembro-chemotherapy (CHT) in advanced non-small cell lung cancer (NSCLC)
Authors: L. Zullo, E. Cella, D. Favero, F. Parisi, C. Dellepiane, G. Rossi, E. Bennicelli, G. Barletta, L. Zinoli, P. Pronzato, L. Del Mastro, C. Genova
Journal: Annals of Oncology (2022)
CN46 Catheter-related venous thrombosis: Experience with blue advance peripherally inserted central catheter (PICC) in a day hospital during the pandemic
Authors: F. Losa, M. Mancha, N. Moragriega, A. Perez, A. Manzana, A. Rios, A. Aranda, E. Cabezudo
Journal: Annals of Oncology (2022)
536P Relacorilant + nab-paclitaxel in patients with recurrent, platinum-resistant ovarian cancer: Phase II subgroup analysis mirroring the patient population of an upcoming phase III study
Authors: N. Colombo, T. Van Gorp, U.A. Matulonis, A. Oaknin, R.N. Grisham, G. Fleming, A. Olawaiye, I.C. Tudor, H.I. Pashova, D. Lorusso
Journal: Annals of Oncology (2022)
87P ctDNA analysis as a prognostic factor for early-stage and oligometastatic patients treated with radiotherapy
Authors: G. Alvarez Cifuentes, A. Santiago, L. Mendez, M. Fueyo, E. López Martínez, R. Soria, I. Martín López, N.S. Durán, R. Álvarez, C.G. Lago, A. Otero Gonzalez, M. Diñeiro, R. Capín, J. Cadiñanos, R. Cabanillas
Journal: Annals of Oncology (2022)
813P Time to development of central nervous system (CNS) metastases (mets) with atezolizumab (A) or placebo (P) combined with vemurafenib (V) + cobimetinib (C): Updated results from the phase III IMspire150 study
Authors: K. Lewis, C. Robert, R. Ramella Munhoz, G. Liszkay, L. de la Cruz Merino, J. Olah, P. Queirolo, J. Mackiewicz, H. Li, Q. Zhu, C. Hertig, N. Paranthaman, E.F. McKenna, R. Gutzmer, G. McArthur, P.A. Ascierto
Journal: Annals of Oncology (2022)
951P Induction osimertinib followed by definitive sequential radiation therapy and/or surgery in unresectable EGFR-mutant stage III NSCLC: An open-label, single-arm, phase II study
Authors: N. Peled, L.C. Roisman, J. Dudnik, E. Dudnik, E. Chernomordikov, S. Keren Rosenberg, W. Shalata, V. Hannes, S. Tsuriel, R. Lichtenburg, A. Allen, D. Hershkovitz, P. Blumenfeld, K. Lavrenkov, W. Kian
Journal: Annals of Oncology (2022)
971TiP Phase III trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8)
Authors: M. Ozguroglu, B. Levy, H. Horinouchi, J. Yu, E. Grainger, P. Phuong, D.A. Peterson, M. Newton, A. Spira
Journal: Annals of Oncology (2022)